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Background: Ongoing CD4 monitoring in patients on antiretroviral ther-
apy (ART) with viral suppression has been questioned. We evaluated the 
probability of CD4 decline in children with viral suppression and CD4 
recovery after 1 year on ART.
Methods: We included children from 8 South African cohorts with rou-
tine HIV-RNA monitoring if (1) they were “responders” [HIV-RNA < 400 
copies/mL and no severe immunosuppression after ≥1 year on ART (time 
0)] and (2) ≥1 HIV-RNA and CD4 measurement within 15 months of time 
0. We determined the probability of CD4 decline to World Health Organi-
zation–defined severe immunosuppression for 3 years after time 0 if viral 
suppression was maintained. Follow-up was censored at the earliest of the 
following dates: the day before first HIV-RNA measurement >400 copies/
mL; day before a >15-month gap in testing and date of death, loss to follow-
up, transfer out or database closure.
Results: Among 5984 children [median age at time 0: 5.8 years (interquartile 
range: 3.1–9.0)], 270 children experienced a single CD4 decline to severe 
immunosuppression within 3 years of time 0 with probability of 6.6% (95% 
CI: 5.8–7.4). A subsequent CD4 measurement within 15 months of the first 
low measurement was available for 63% of children with CD4 decline and 
86% showed CD4 recovery. The probability of CD4 decline was lowest 
(2.8%) in children aged 2 years or older with no or mild immunosuppression 
and on ART for <18 months at time 0. This group comprised 40% of children.
Conclusions: This finding suggests that it may be safe to stop routine CD4 
monitoring in children older than 2 years and rely on virologic monitoring 
alone.
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(Pediatr Infect Dis J 2015;34:1361–1364)
For over 20 years, CD4 cell count measurements have been central to the management of patients with HIV to assess disease pro-
gression, guide decisions about antiretroviral therapy (ART) initia-
tion and monitor treatment response.1,2 Although CD4 measurement 
continues to play an important role as a marker of disease progres-
sion and to identify the risk of opportunistic infections, the value of 
CD4 measurements for monitoring treatment response and diagnos-
ing failure in settings where virologic monitoring is also available 
have come into question.3 Studies from the United States,4 Europe,5 
Uganda6 and South Africa7 have shown that, among adult patients 
who are stable on ART and virologically suppressed, CD4 decline is 
rare, and when it does occur, decline is usually transient, suggesting 
that repeated CD4 monitoring after viral suppression on ART is not 
necessary. Further CD4 measurement in a virally suppressed patient 
rarely contributes to clinical decision making.8 Studies among adult 
patients in the United States,9 the United Kingdom,10 Australia,8 
Kenya11 and South Africa12 have all estimated substantial programme 
cost savings if routine CD4 monitoring is reduced or stopped. Guide-
lines issued by the Southern African HIV Clinicians Society in 2013 
recommend that for adult patients with routine viral load monitoring, 
there is no need to continue CD4 testing once CD4 is >200 cells/
mm3 and viral load is suppressed. CD4 testing is recommended 
if virologic or clinical failure occurs.13 In 2014, the World Health 
Organization (WHO) issued a technical document based on expert 
consultation, which concluded that if viral load is available routinely, 
CD4 monitoring could be reduced or stopped altogether in virologi-
cally suppressed patients.14 However, the absence of data for children 
was noted. We assessed CD4 changes in a cohort of virologically 
suppressed children on ART in South Africa.
MATERIALS AND METHODS
We conducted a retrospective analysis of data from 8 cohorts 
contributing to the International epidemiologic Databases to Evalu-
ate AIDS Southern Africa (IeDEA-SA) collaboration (www.iedea-
sa.org). All cohorts have ethics approval from their respective local 
institutional review boards to contribute data to IeDEA-SA, and 
IeDEA-SA has been approved by the Human Research Ethics 
Committees of the Universities of Cape Town and Bern where the 
IeDEA-SA data centers are located.
Antiretroviral naïve children at sites with routine (at least 
annual) HIV-RNA and CD4 monitoring were included in the 
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analysis if they had ≥12 months follow-up on ART. Children 
entered the analysis on the first date that they met the criteria for 
an adequate response to treatment (defined as HIV-RNA <400 cop-
ies/mL and simultaneous CD4 with no severe immunosuppres-
sion after ≥9 months on ART). The time when a child first met 
these criteria was designated time 0. We evaluated all subsequent 
paired HIV-RNA and CD4 measures to determine the probabil-
ity of a CD4 decline to severe immunosuppression after time 0 in 
children who remained virologically suppressed. Children who did 
not have at least 1 subsequent paired HIV-RNA and CD4 measure-
ment within 15 months of time 0 were excluded. We used the WHO 
2006 criteria to define severe immunosuppression: CD4 < 20%/ 
750 cells/mm3 (age: 12–35 months), CD4 < 15%/350 cells/mm3 
(age: 36–59 months) and CD4 < 15%/200 cells/mm3 (age: ≥5 
years).15 Data were censored the day before the first HIV-RNA 
measurement >400 copies/mL, the first >15-month gap in testing 
or last date of follow-up because of death, loss to follow-up (LTFU) 
or transfer out. LTFU was defined as no visit for 9 months before 
database closure.
Associations between characteristics at time 0 and CD4 
decline were assessed using Cox-proportional hazards models. 
Multivariable models included variables considered a priori to 
affect the probability of CD4 decline, including age and duration 
on ART at time 0 and degree of immunosuppression both at time 
0 and at ART initiation. Severe immunosuppression was defined as 
mentioned earlier. The definition of no/mild immunosuppression 
was based on the WHO criteria: CD4 ≥ 25% and 1000 cells/mm3 
in a child younger than 5 years or ≥20% and 500 cells/mm3 in a 
child aged 5 years or older.15 Hazards proportionality was assessed 
by the analysis of scaled Schoenfeld residuals. All analyses were 
performed using Stata version 12.0 (College Station, TX).
RESULTS
Among 9503 children who had been on ART for ≥12 months, 
5984 met the inclusion criteria for this analysis. The reasons for 
exclusion are shown in Figure, Supplemental Digital Content 1, 
http://links.lww.com/INF/C263. The characteristics of included and 
excluded children are summarized in Table, Supplemental Digital 
Content 2, http://links.lww.com/INF/C264. Median (interquartile 
range) age at time 0 in children included in the analysis was 5.8 (3.1–
9.0) years, and median (interquartile range) time on ART was 12.9 
(11.3–18.0) months. First-line regimen information was recorded for 
5696 (95.1%) children, of whom 31.9% initiated lopinavir-/ritonavir-
based ART, whereas 61.6% and 3.5% initiated efavirenz (EFV)- and 
nevirapine-based regimens, respectively. During the following 3 
years, 270 children experienced a CD4 decline to severe immuno-
suppression, with a probability of 6.6% (95% CI: 5.8–7.4). Most 
declines were not sustained: a subsequent CD4 measurement within 
15 months of the first measurement was available for 169 (63%) of 
270 children with a CD4 decline; the majority (n = 145, 86%) no 
longer had severe immunosuppression at the next measurement. 
Only 3 of these children underwent a treatment change between the 
first and subsequent CD4 measurement: 1 child switched to second 
line [change of both nucleoside reverse transcriptase inhibitors and 
change from EFV to lopinavir/ritonavir (LPV/r)]; 1 child had a sin-
gle-drug change from LPV/r to EFV and in the third child, ritonavir 
superboosting was added to the LPV/r-based regimen as tuberculosis 
treatment was started. Among the 270 children with CD4 decline, 
outcomes in the following year were as follows: 85.2% remained in 
care, 1.1% had died, 1.9% were lost to follow-up and 11.9% had 
been transferred to another site. In children with CD4 decline who 
remained in care but did not have a repeat CD4 measurement for 
inclusion in the analysis (n = 84), the main reason (n = 47) was that 
there was <1 year of follow-up from the date of low CD4 measure-
ment to the date of database closure. Hence, there was insufficient 
time for a repeat CD4 as national guidelines recommended annual 
CD4 monitoring. Other reasons were that the next CD4 measurement 
was >15 months after the date of decline (n = 23) or that the child was 
not virologically suppressed at the next CD4 measurement (n = 8). 
Six children had no subsequent CD4 measurement despite >365 days 
of follow-up before database closure.
The 3-year probability of CD4 decline to severe immuno-
suppression was lowest (2.8%; 95% CI: 2.1–3.8) in children with 
the following characteristics: ≥2 years old at time 0, met the criteria 
for an adequate response to ART within 18 months of starting treat-
ment and good immunologic response (ie, had no/mild rather than 
severe immunosuppression at time 0). This subgroup comprised 
40% (n = 2368) of all children included in the analysis (Fig. 1; see 
Table, Supplemental Digital Content 3, http://links.lww.com/INF/
C265). The following characteristics at time 0 were associated with 
an increased risk of CD4 decline: age < 2 years [adjusted hazard 
ratio (aHR): 2.80; 95% CI: 1.95–4.01], moderate versus no/mild 
immunosuppression (aHR: 2.89; 95% CI: 2.14–3.89) and taking 
longer than 18 months to respond adequately to ART (aHR: 1.51; 
FIGURE 1. ??????????????????????????????????????????? ?????????????????????????????????????????? ???????????????????????????
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95% CI: 1.08–2.12). In addition, severe immunosuppression at 
ART initiation was associated with an increased risk of CD4 decline 
(aHR: 1.96; 95% CI: 1.21–3.18). The groups with high (≥20%) risk 
of CD4 decline were those younger than 2 years at time 0 who 
either took >18 months to respond to ART or were still moderately 
immunosuppressed at time 0. These comprised only 3.3% (n = 195) 
of all children included in the study.
DISCUSSION
The value of continued CD4 monitoring for stable patients 
in settings where viral load is available has been questioned. The 
findings of our study carried out in a large pediatric population 
across several treatment sites in South Africa with both routine 
HIV-RNA and CD4 monitoring concur with reports among adult 
patients and suggest that the risk of CD4 decline in virologically 
suppressed children on ART is low, especially those aged >2 years 
who have attained no/mild immunosuppression. This finding indi-
cates that it may be safe to reduce CD4 monitoring in virologically 
suppressed children aged >2 years on ART.
The risk of CD4 decline was higher in those aged <2 years 
at entry into the study, especially if their immune responses were 
slower and less robust. As children had to have at least 12 months of 
follow-up on ART at study entry, these children would all have been 
1–2 years of age at study entry, and so would have been followed 
up during the period when there is a biologic age–related rapid 
decline in CD4 count.16,17 This age-related decline may explain 
their increased risk of CD4 values falling to severe immunosup-
pression, especially if initial CD4 recovery was suboptimal. Further 
research needs to evaluate the clinical implications of CD4 decline 
at younger ages to determine whether there is a need for ongoing 
CD4 monitoring during this period of biologic rapid CD4 decline.
The current rationale for CD4 monitoring includes deter-
mining the need for ongoing co-trimoxazole prophylaxis; however, 
recent data have suggest that there is a benefit to continuing co-tri-
moxazole prophylaxis irrespective of CD4 count. A recent trial of 
co-trimoxazole prophylaxis in HIV-infected children on ART dem-
onstrated substantial protection of prolonged co-trimoxazole against 
hospitalizations.18 Revised WHO 2014 guidelines recommended 
lifelong co-trimoxazole for HIV-infected children in settings where 
malaria and/or severe bacterial infections are highly prevalent.19
CD4 monitoring could also have a role in identifying 
patients at risk of opportunistic infections. In the context of ongo-
ing virological suppression this need is likely to be small and the 
importance of this role depends on the availability and cost-effec-
tiveness of interventions to diagnose and treat such illnesses. As 
our study lacked detailed data on opportunistic infections, we could 
not examine whether CD4 declines were associated with increased 
opportunistic infection risk, or whether there were any clinical 
interventions in response to low CD4 values. However, it is reas-
suring that most declines were transient without treatment changes 
in the majority of children and that mortality and LTFU in the year 
after a CD4 decline were low. However, our study was limited to 
South African sites with capacity for electronic data collection, and 
findings may not be generalizable to other regions of the world with 
children of different genetic background,16 different frequency of 
viral load measurement, antiretroviral regimens and opportunistic 
infection risk. Therefore, further research is encouraged to confirm 
these findings in other settings and over a longer duration.
The role of CD4 cell measurement in guiding treatment ini-
tiation for children may also be diminishing, given recent changes in 
guidelines for starting pediatric treatment. For programmatic reasons, 
WHO currently recommends that all adults, adolescents and children 
should be initiated on ART irrespective of CD4 cell count.20 Several 
countries are already providing or considering immediate ART to all 
children <15 years of age.21,22 However, although programmatically this 
may increase the current inadequate levels of pediatric treatment cov-
erage, the current evidence regarding the individual clinical benefit of 
immediate ART initiation in children aged 5–14 years is limited, and a 
number of countries will likely continue to rely on CD4 to guide treat-
ment initiation decisions for some years to come.
Thus, measurement of CD4 cell count will remain an impor-
tant tool for assessing baseline health status, investigation for cer-
tain opportunistic infections and initiation of ART in older chil-
dren. However, in settings where both CD4 and viral load testing 
are available and patients are stable on ART, this study suggests that 
ongoing routine monitoring of CD4 in children older than 2 years 
has limited additional value, and consideration should be given to 
reducing the frequency of CD4 monitoring or dropping its routine 
use altogether unless clinical deterioration or viral rebound occurs. 
This could simplify programmes allowing for increased treatment 
access and for resources to be directed at ensuring that routine viral 
load measurement is undertaken satisfactorily.
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